title: Reversal of quinpirole inhibition of ventral tegmental area neurons is linked to the phosphatidylinositol system and is induced by agonists linked to G(q).
abstract: Putative dopaminergic (pDAergic) ventral tegmental area neurons play an important role in brain pathways related to addiction. Extended exposure of pDAergic neurons to moderate concentrations of dopamine (DA) results in a time-dependent decrease in sensitivity of pDAergic neurons to DA inhibition, a process called dopamine inhibition reversal (DIR). We have shown that DIR is mediated by phospholipase C and conventional protein kinase C through concurrent stimulation of D2 and D1-like receptors. In the present study, we further characterized this phenomenon by using extracellular recordings in brain slices to examine whether DIR is linked to phosphatidylinositol (PI) or adenylate cyclase (AC) second-messenger pathways. A D1-like dopaminergic agonist associated with PI turnover (SKF83959), but not one linked to AC (SKF83822), promoted reversal of inhibition produced by quinpirole, a dopamine D2-selective agonist. Other neurotransmitter receptors linked to PI turnover include serotonin 5-HT(2), α(1)-adrenergic, neurotensin, and group I metabotropic glutamate (mGlu) receptors. Both serotonin and neurotensin produced significant reversal of quinpirole inhibition, but agonists of α(1)-adrenergic and group I mGlu receptors failed to significantly reverse quinpirole inhibition. These results indicate that some agonists that stimulate PI turnover can facilitate desensitization of D2 receptors but that there may be other factors in addition to PI that control that interaction.
authors.affiliation: Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL 60612-7342, USA.
authors.forename: Sudarat
authors.initials: S
authors.lastname: Nimitvilai
authors.forename: Maureen A
authors.initials: MA
authors.lastname: McElvain
authors.forename: Devinder S
authors.initials: DS
authors.lastname: Arora
authors.forename: Mark S
authors.initials: MS
authors.lastname: Brodie
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D015259:Dopamine Agents / Q000494:pharmacology*; D059290:Dopaminergic Neurons / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000378:metabolism*; D066298:In Vitro Techniques; D007650:Ketanserin / Q000494:pharmacology; D009496:Neurotensin / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism*; D019257:Quinpirole / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D012701:Serotonin / Q000494:pharmacology; D017557:Ventral Tegmental Area / Q000166:cytology*
chemical_list: D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D010716:Phosphatidylinositols; D010656:Phenylephrine; D019257:Quinpirole; D012701:Serotonin; D009496:Neurotensin; D007650:Ketanserin; D043802:GTP-Binding Protein alpha Subunits, Gq-G11